Our study suggests that the therapeutic effects of anti-PLVAP-Fab-TF for treatment of HCC best be achieved through infusion into a tumor feeding artery similar to the current TACE/TAE procedures. The gene discussed is TF; the disease is hepatocellular carcinoma.